Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Rhea-AI Summary

Pulse Biosciences (PLSE) reported Q3 2024 financial results and business updates. The company placed nsPFA Percutaneous Electrode Systems at seven U.S. sites and treated 9 patients in their atrial fibrillation study. They also treated over 50 patients with their nano-PFA 360° Cardiac Catheter. Financial highlights include GAAP costs of $13.7M (up from $11.3M YoY), GAAP net loss of $12.7M (vs $10.6M YoY), and cash position of $79.0M as of September 30, 2024. The company raised $60M through a rights offering in July 2024, with potential for additional $66M through warrant exercises.

Positive

• Raised $60M through rights offering with potential for additional $66M through warrants
• Strong cash position of $79.0M as of September 30, 2024
• Expanded clinical trials with 50+ patients treated with nano-PFA 360° Cardiac Catheter
• Placed systems at seven U.S. sites for commercial pilot program

Negative

• Increased GAAP net loss to $12.7M from $10.6M YoY
• Higher operating expenses: GAAP costs up to $13.7M from $11.3M YoY
• Cash burn of $8.5M in Q3 2024

Insights

Financial Analyst

The Q3 2024 results reveal significant operational expansion but growing losses. Total GAAP expenses increased to $13.7 million, up $2.4 million from the prior year, while the non-GAAP net loss widened to $9.4 million. The cash position remains strong at $79 million, bolstered by a $60 million rights offering.

The company's strategic focus on three nano-PFA devices and planned pivotal trials in 2025 suggests substantial upcoming R&D investments. The potential for additional $66 million through warrant exercises provides financial flexibility, though execution depends on achieving specific stock price thresholds of $16.50 and $22.00.

Quarterly cash burn remains stable at $8.5 million, indicating disciplined spending despite expansion. With current cash reserves, the company has approximately 9 quarters of runway at current burn rates, excluding potential warrant proceeds.

Medical Research Analyst

The clinical progress across three therapeutic areas shows promising momentum. The pilot program for the Percutaneous Electrode System in thyroid nodules and the expansion of AF trials demonstrate advancing commercialization efforts. Key developments include:

• Treatment of 9 patients in the surgical AF study
• Over 50 patients treated with the nano-PFA 360° Cardiac Catheter
• Seven U.S. sites participating in the percutaneous electrode pilot program

The addition of prominent medical advisors Dr. Kenigsberg and Dr. Natale strengthens the company's clinical expertise. The planned 2025 pivotal trials for all three devices represent critical milestones for FDA approval and market entry. Early clinical data suggesting superior cell eradication compared to existing treatments could position nano-PFA as a disruptive technology in ablation therapies.

MIAMI--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024.

Recent Business Highlights

Soft Tissue Ablation

• Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters.
• The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in the United States as a treatment for benign thyroid nodules.
• Clinical data from the European feasibility study on using nano-PFA to treat benign thyroid nodules will be presented at the American Thyroid Association Conference as an oral abstract on October 31, 2024.

Surgical AF Ablation

• Treated 9 patients and opened a second study site as part of the multi-center, first-in-human atrial fibrillation (AF) feasibility study underway in Europe.
• The Company expects to submit an IDE, enabling it to commence its pivotal clinical trial in mid-2025 to support a premarket approval (PMA) application for FDA approval to commercialize the nano-PFA Cardiac Surgical System in the United States as a treatment for AF.

Endocardial Catheter AF Ablation

• Treated over 50 patients with the nano-PFA 360° Cardiac Catheter and engaged two additional European clinical study sites in the first-in-human feasibility study for the treatment of AF.
• Announced the appointment of Dr. David Kenigsberg as Chief Medical Officer for Electrophysiology and the addition of Dr. Andrea Natale to its electrophysiology medical advisory board, joining existing advisors Dr. Vivek Reddy and Dr. Jacob Koruth.
• The Company expects to commence a U.S. IDE pivotal clinical study sometime in the middle of 2025.

“In the third quarter we made significant progress toward delivering the benefits of nano-PFA to patients and providers around the world. Our clinical work with each of our three devices continues to suggest that our differentiated nano-PFA technology has the potential to improve treatments for several disease states by eradicating cells in a better way than currently available modalities,” said Burke T. Barrett, President and Chief Executive Officer of Pulse Biosciences. “The work we have done to date positions us to begin pivotal clinical trials in the U.S. for each device next year and to also share select European trial data at medical conferences in the future. We are building our team and the infrastructure required to support our clinical and regulatory initiatives and anticipated growth, starting with commercial use of the nsPFA Percutaneous Electrode System in the coming quarters.”

Third Quarter 2024 Financial Results

Total GAAP costs and expenses, representing research and development and general and administrative expenses, for the three months ended September 30, 2024, were $13.7 million, an increase of $2.4 million, compared to $11.3 million in the prior year period. The increase was primarily driven by stock-based compensation and other compensation and administrative expenses to support the expanding organization and the advancement of our nano-PFA devices. Non-GAAP costs and expenses for the three months ended September 30, 2024, were $10.4 million, an increase of $1.2 million compared to $9.2 million in the prior year period.

GAAP net loss for the three months ended September 30, 2024 was ($12.7) million compared to ($10.6) million for the three months ended September 30, 2023. Non-GAAP net loss for the three months ended September 30, 2024 was ($9.4) million compared to ($8.5) million for the three months ended September 30, 2023.

Cash and cash equivalents totaled $79.0 million as of September 30, 2024. The cash balance as of September 30, 2024 includes $60 million in gross proceeds received from the rights offering that closed in July of 2024. The Company has the potential to raise an additional up to $66 million through the exercise of warrants associated with this rights offering. Each warrant is exercisable for $11 per share, which equals 110% of the subscription price for the Units. Warrants are exercisable immediately. Half of the warrants are redeemable by the Company if the Company’s stock trading price exceeds $16.50 for twenty consecutive trading days and the other half of the warrants are redeemable by the Company if its stock trading price exceeds $22.00 for twenty consecutive trading days. Holders of the warrants have the right to exercise them at any time until they are redeemed or expire.

Cash used in the third quarter of 2024 was $8.5 million, excluding financing activity, compared to $8.7 million used in the second quarter of 2024 and $8.7 million in the third quarter of 2023.

Reconciliations of GAAP to non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call today, October 30, 2024, beginning at 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing 1-877-407-0752 for domestic callers or 1-201-389-0912 for international callers. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida, and maintains its office in Hayward, California.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Non-GAAP Financial Measures

In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization and restructuring charges. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:

Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating the Company’s non-GAAP cost and expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of time-based and performance-based options, such as options that vest as a result of the Company’s market capitalization. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons from period to period.

Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP cost and expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.

Restructuring charges. The Company has excluded restructuring charges in calculating its non-GAAP cost and expenses and net loss measures. Restructuring programs involve discrete initiatives designed to improve operating efficiencies and include employee termination, contract termination, and other exit costs associated with the restructuring program. The Company believes that excluding discrete restructuring charges allows for better comparisons from period to period.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s future fundraising efforts and whether those efforts will be successful or allow the Company to continue current operations as planned, and statements concerning the Company’s future clinical and regulatory initiatives anywhere in the world, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

PULSE BIOSCIENCES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except per share amounts)
(Unaudited)
		September 30,				December 31,
		2024				2023
ASSETS
Current assets:
Cash and cash equivalents		$	79,033			$	44,365
Prepaid expenses and other current assets			1,381				963
Total current assets			80,414				45,328
Property and equipment, net			1,221				1,528
Intangible assets, net			1,386				1,886
Goodwill			2,791				2,791
Right-of-use assets			6,588				7,256
Other assets			646				365
Total assets		$	93,046			$	59,154
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	1,727			$	1,836
Accrued expenses			3,821				3,814
Lease liability, current			1,193				1,058
Total current liabilities			6,741				6,708
Lease liability, less current			7,174				8,086
Total liabilities			13,915				14,794
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding			—				—
Common stock, $0.001 par value: authorized – 500,000 shares; issued and outstanding – 61,516 shares and 55,144 shares at September 30, 2024 and December 31, 2023, respectively			62				55
Additional paid-in capital			450,184				381,220
Accumulated other comprehensive income (loss)			—				—
Accumulated deficit			(371,115	)			(336,915	)
Total stockholders’ equity			79,131				44,360
Total liabilities and stockholders’ equity		$	93,046			$	59,154

PULSE BIOSCIENCES, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
		Three-Month Periods Ended								Nine-Month Periods Ended
		September 30,								September 30,
		2024				2023				2024				2023
Revenues:
Product revenues		$	—			$	—			$	—			$	—
Total revenues			—				—				—				—
Cost and expenses:
Research and development			7,703				7,472				21,674				19,998
General and administrative			5,952				3,780				14,322				11,043
Total cost and expenses			13,655				11,252				35,996				31,041
Loss from operations			(13,655	)			(11,252	)			(35,996	)			(31,041	)
Other income:
Interest income, net			975				686				1,796				764
Total other income			975				686				1,796				764
Net loss			(12,680	)			(10,566	)			(34,200	)			(30,277	)
Comprehensive loss		$	(12,680	)		$	(10,566	)		$	(34,200	)		$	(30,277	)
Net loss per share:
Basic and diluted net loss per share		$	(0.21	)		$	(0.19	)		$	(0.60	)		$	(0.64	)
Weighted average shares used to compute net loss per common share — basic and diluted			61,066				56,866				57,169				47,288
		Three-Month Periods Ended								Nine-Month Periods Ended
		September 30,								September 30,
Stock Based Compensation Expense:		2024				2023				2024				2023
Research and development			1,108				982				3,058				1,758
General and administrative			1,874				816				3,735				2,079
Total stock-based compensation expense		$	2,982			$	1,798			$	6,793			$	3,837

Reconciliation of GAAP to Non-GAAP Financial Measures
The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures:
(In thousands)
(Unaudited)
	Three-Month Periods Ended								Nine-Month Periods Ended
		September 30,								September 30,
		2024				2023				2024				2023
Reconciliation of GAAP to non-GAAP Research and development:
GAAP Research and development	$	7,703			$	7,472			$	21,674			$	19,998
Less: Stock-based compensation expense		(1,108	)			(982	)			(3,058	)			(1,758	)
Less: Depreciation and amortization		(47	)			(55	)			(152	)			(172	)
Less: Restructuring		—				—				—				(38	)
Non-GAAP Research and development	$	6,548			$	6,435			$	18,464			$	18,030
Reconciliation of GAAP to non-GAAP General and administrative:
GAAP General and administrative	$	5,952			$	3,780			$	14,322			$	11,043
Less: Stock-based compensation expense		(1,874	)			(816	)			(3,735	)			(2,079	)
Less: Depreciation and amortization		(246	)			(242	)			(740	)			(730	)
Less: Restructuring		—				—				—				(5	)
Non-GAAP General and administrative	$	3,832			$	2,722			$	9,847			$	8,229
Reconciliation of GAAP to non-GAAP Cost and expenses:
GAAP Cost and expenses	$	13,655			$	11,252			$	35,996			$	31,041
Less: Stock-based compensation expense		(2,982	)			(1,798	)			(6,793	)			(3,837	)
Less: Depreciation and amortization		(293	)			(297	)			(892	)			(902	)
Less: Restructuring		—				—				—				(43	)
Non-GAAP Cost and expenses	$	10,380			$	9,157			$	28,311			$	26,259
Reconciliation of GAAP to non-GAAP Net loss:
GAAP Net loss	$	(12,680	)		$	(10,566	)		$	(34,200	)		$	(30,277	)
Add: Stock-based compensation expense		2,982				1,798				6,793				3,837
Add: Depreciation and amortization		293				297				892				902
Add: Restructuring		—				—				—				43
Non-GAAP Net loss	$	(9,405	)		$	(8,471	)		$	(26,515	)		$	(25,495	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030332516/en/

Investors:

Pulse Biosciences, Inc.

Burke T. Barrett, President and CEO

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

FAQ

What was Pulse Biosciences (PLSE) Q3 2024 net loss?

Pulse Biosciences reported a GAAP net loss of $12.7 million for Q3 2024, compared to $10.6 million in Q3 2023.

How much cash does PLSE have as of September 30, 2024?

Pulse Biosciences had $79.0 million in cash and cash equivalents as of September 30, 2024, including $60 million raised from a rights offering in July 2024.

When will PLSE begin its pivotal clinical trials for AF treatment?

Pulse Biosciences expects to commence its U.S. pivotal clinical trials for AF treatment in mid-2025.

How many patients has PLSE treated with its nano-PFA 360° Cardiac Catheter?

Pulse Biosciences has treated over 50 patients with its nano-PFA 360° Cardiac Catheter in its first-in-human feasibility study.